The Wall Street Journal
Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.
The Food and Drug Administration's approval of Halaven in November
for treating late-stage breast cancer was a triumph of chemistry and
tenacious research. Its path, extending nearly three decades from the
first studies, demonstrates not only potential benefits but also some of
the hurdles in the hunt within nature's bounty for drugs of the future... Read More